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Abstract
Introduction—For older men who undergo bone mineral density (BMD) testing, the optimal 
osteoporosis screening schedule is unknown. Time-to-disease estimates are necessary to inform 
screening intervals.
Methods—A prospective cohort study of 5,415 community-dwelling men aged ≥65 years 
without hip or clinical vertebral fracture or antifracture treatment at baseline was conducted. 
Participants had concurrent BMD and fracture follow-up between 2000 and 2009, and additional 
fracture follow-up through 2014. Data were analyzed in 2015. Time to incident osteoporosis 
(lowest T-score ≤ −2.50) for men without baseline osteoporosis, and time to hip or clinical 
vertebral fracture or major osteoporotic fracture for men without or with baseline osteoporosis, 
were estimated.
Results—Nine men (0.2%) with BMD T-scores > −1.50 at baseline developed osteoporosis 
during follow-up. The adjusted estimated time for 10% to develop osteoporosis was 8.5 (95% 
CI=6.7, 10.9) years for those with moderate osteopenia (lowest T-score, −1.50 to −1.99) and 2.7 
(95% CI=2.1, 3.4) years for those with advanced osteopenia (lowest T-score, −2.00 to −2.49) at 
baseline. The adjusted times for 3% to develop a first hip or clinical vertebral fracture ranged from 
7.1 (95% CI=6.0, 8.3) years in men with baseline T-scores > −1.50 to 1.7 (95% CI=1.0, 3.1) years 
in men with baseline osteoporosis.
Conclusions—Men aged 65 years and older with femoral neck, total hip, and lumbar spine 
BMD T-scores > −1.50 on a first BMD test were very unlikely to develop osteoporosis during 
follow-up. Additional BMD testing may be most informative in older men with T-scores ≤ −1.50.
Introduction
Osteoporosis-related fractures impose a significant burden to older men.1 One in four elderly 
men will sustain a fragility fracture during their remaining lifetime,2 with an exponential 
increase in fracture incidence after age 75 years.3 Men also have a higher 1-year mortality 
rate after hip fracture compared with women.4–6 A 2012 RCT of older men with 
osteoporosis treated with zoledronic acid demonstrated significant reduction in the primary 
endpoint of radiographic vertebral fracture.7 Similarly, an earlier meta-analysis suggested 
that risedronate treatment in men aged 55–76 years with osteoporosis by bone mineral 
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density (BMD) criteria or with secondary causes of osteoporosis, with or without existing 
vertebral fracture, was associated with radiographic vertebral fracture reduction.8 Owing to 
the serious consequences of fracture and available antifracture treatment, several 
organizations9–12 have endorsed identification of osteoporosis in older men through BMD 
testing, but an interval of measurement has not been recommended.
In 2011, the U.S. Preventive Services Task Force concluded evidence was insufficient to 
assess the balance of benefits and harms of osteoporosis screening in men (Grade I),13 thus 
highlighting a need for developing a screen/treat strategy to identify elderly men at increased 
fracture risk. A 2007 cost-effectiveness analysis suggested that a screen/treat strategy may 
be cost effective for men aged 65 years or older with a prior clinical fracture and for men 
aged 80 years or older without a prior fracture, assuming a societal willingness to pay 
$50,000 per quality-adjusted life year gained.14 It is unknown what proportion of men will 
develop osteoporosis prior to experiencing a fragility fracture. In addition, the time frame for 
men at specific baseline BMD levels to develop a disabling fracture event is uncertain.
The objective of this study was to inform decisions about BMD testing intervals by 
estimating the time to development of osteoporosis by BMD criteria and the time to 
development of hip or clinical vertebral fracture in a cohort of 5,415 men aged 65 years and 
older without prior hip or clinical vertebral fracture or osteoporosis treatment. Based on a 
previous study of older women,15 it was hypothesized that men with baseline T-scores ≤ 
−1.50 would develop osteoporosis significantly more rapidly than men with higher T-scores. 
Men with baseline osteoporosis were expected to have a more rapid transition to fracture 
than men with T-scores > −2.50.
Methods
Setting and Participants
The Osteoporotic Fractures in Men (MrOS) Study cohort comprised 5,994 community-
dwelling, ambulatory men aged ≥65 years who met these inclusion criteria at baseline:
1. ability to walk without the assistance of another;
2. absence of bilateral hip replacements;
3. ability to provide self-reported data;
4. planned residence near a clinical site for the duration of the study;
5. absence of a medical condition that (in the judgment of the investigator) would 
result in imminent death; and
6. ability to understand and sign an informed consent.
Participants had to provide written informed consent, complete a self-administered 
questionnaire, attend the clinic visit, and complete at least the anthropometric, dual energy 
x-ray absorptiometry (DXA), and vertebral x-ray procedures. Recruitment relied primarily 
on community-based mailings, supplemented at some sites with local strategies 
(advertisements, presentations) to enhance the recruitment of minority groups. The study 
enrolled participants and completed the baseline examination from March 2000 through 
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April 2002.16,17 The study protocol and consent documents were approved by IRB review 
committees at six clinical sites in the U.S. (Birmingham, AL; Minneapolis, MN; Palo Alto, 
CA; Pittsburgh, PA; Portland, OR; San Diego, CA).
The plan for the longitudinal analysis was approved by the IRB for the University of North 
Carolina. DXA BMD imaging was obtained over 8.7 years of follow-up, including the 
baseline visit, 2000–2002; Year 2, 2002–2003; Year 3, 2003–2005; Year 5, 2005–2006; and 
Year 7, 2007–2009. Participants were also followed every 4 months by postcard or telephone 
to ascertain fractures, with fracture follow-up through November 2014. Data were analyzed 
in 2015. All fractures were adjudicated by central review of radiology reports.16 Men were 
eligible for the primary analysis if they were representative of the screened population (i.e., 
they had no history of osteoporosis diagnosis, hip or clinical vertebral fracture, or 
antifracture treatment at baseline). Men who had osteoporosis without antifracture treatment 
or hip or clinical vertebral fracture at baseline were eligible to participate in the 
osteoporosis-to-fracture analysis.
Measures
The 1994 WHO Technical Report18 defined osteoporosis as BMD T-score ([BMD of 
participant – mean BMD of young reference population]/SD of BMD of reference 
population) ≤ −2.5 at the lumbar spine, hip, or distal radius. The International Osteoporosis 
Foundation19 and the International Society for Clinical Densitometry20 recommend that a 
uniform Caucasian (non–race adjusted) female reference database should be used to 
calculate T-scores for men of all ethnic groups. The International Osteoporosis Foundation 
justifies this convention by noting that for any age and BMD at the femoral neck, the risk of 
hip fracture or a major osteoporotic fracture is approximately the same in men and women.19 
Accordingly, T-scores were calculated at the femoral neck, total hip, and lumbar spine using 
National Health and Nutrition Examination Study III BMD norms for white women aged 
20–29 years21,22 in the main analysis.
Participants were categorized into these baseline T-score groups: higher BMD—lowest T-
score at the femoral neck, total hip, or lumbar spine > −1.50; moderate osteopenia—lowest 
T-score at any site −1.50 to −1.99; advanced osteopenia—lowest T-score at any site −2.00 to 
−2.49; and osteoporosis—lowest T-score at any site ≤ −2.50.
The primary outcome was the time interval for 10% of participants without osteoporosis at 
baseline to develop osteoporosis before initiation of a Food and Drug Administration–
approved agent for the treatment of osteoporosis (bisphosphonate, calcitonin, or teriparatide) 
and before development of a first hip or clinical vertebral fracture. Because clinicians may 
potentially treat a patient before BMD is in the osteoporosis range, “antifracture treatment” 
is used synonymously with the Food and Drug Administration–approved agents for 
osteoporosis treatment throughout this paper.
The secondary outcome was the time for 3% of participants to develop a first hip or clinical 
vertebral fracture before initiation of an antifracture treatment agent and before development 
of osteoporosis (for those without osteoporosis at baseline). This study included both 
nontraumatic and traumatic fractures in the fracture endpoints because clinical 
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misclassification of fracture etiology is common, and a falsely low fracture count would lead 
to inappropriately long estimates of time to fracture.
The tertiary outcome was the time for 3% of participants to develop a first nontraumatic or 
traumatic major osteoporotic (hip, clinical vertebral, proximal humerus, or wrist) fracture 
before initiation of antifracture treatment and before development of osteoporosis (for those 
without osteoporosis at baseline).
Statistical Analysis
The time for 10% of men without osteoporosis at baseline to develop osteoporosis prior to 
hip or clinical vertebral fracture and prior to initiation of antifracture treatment was 
estimated from parametric log-logistic regression models of the cumulative incidence 
quantile as defined in Peng and Fine, 23–27 based on interval-censored data. The analysis 
was stratified by the baseline categories of higher BMD and moderate and advanced 
osteopenia. The time origin was the first study examination with a BMD measurement that 
included femoral neck, total hip, and lumbar spine measurements, with follow-up BMD 
measurements at one or more sites continuing until the study examination preceding death or 
dropout. In the time-to-osteoporosis analysis, first reported use of antifracture treatment, hip 
or clinical vertebral fracture, and death were competing risks.
Using separate models for men without versus with osteoporosis at baseline, competing risk 
analyses were conducted to estimate the cumulative incidence functions for time to first hip 
or clinical vertebral fracture, and for time to major osteoporotic fracture, based on known 
fracture dates prior to osteoporosis and treatment. The corresponding time intervals for 3% 
of participants to transition to each fracture outcome were determined for the higher BMD 
and moderate and advanced osteopenia groups. First reported use of antifracture treatment, 
incident osteoporosis (for men without osteoporosis at baseline) and death were competing 
risks in the time-to-fracture analyses. Results from all models were adjusted for race, and 
baseline mean-centered age and BMI.
Sensitivity analyses were conducted to evaluate and determine the most appropriate 
parametric models for estimates of time to osteoporosis and time to fracture. All analyses 
were performed using SAS, version 9.4.
Results
Of the 5,994 men in the cohort, one was not eligible for this study because he was aged <65 
years at baseline. After other eligibility criteria were applied (Appendix Figure 1), baseline 
characteristics of the 5,415 participants in the analytic cohort were tabulated (Table 1). The 
mean age of the cohort was 73.6 years, and the mean BMI was 27.4 kg/m2 (overweight). 
About three fourths of the men (4,203 of 5,415) had higher BMD at baseline, whereas 180 
(3.3%) had baseline osteoporosis. Within each baseline T-score range, the following 
proportions of men developed osteoporosis before initiation of antifracture treatment and 
before a first hip or clinical vertebral fracture: higher BMD, 9/4,203 (0.2%); moderate 
osteopenia, 35/680 (5.1%), and advanced osteopenia, 73/352 (20.7%).
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Within the higher BMD category, 107 men (3.4% of 3,177) with baseline T-scores ≥ −1.00 
and 62 men (6.0% of 1,026) with baseline T-scores between −1.01 and −1.49 had a hip or 
clinical vertebral fracture by the end of study follow-up (combined results for these T-score 
groups are in Table 3). Of the total of 371 men without baseline osteoporosis who sustained 
a first hip (n=219) or clinical vertebral (n=152) fracture, 69 (18.6%) developed osteoporosis 
before hip or clinical vertebral fracture, and 24 (6.5%) received antifracture treatment prior 
to the fracture. Of these 371 men, 317 had a first hip or clinical vertebral fracture before a 
competing risk occurred (Table 1.)
The estimated time for 10% of men without osteoporosis at baseline to subsequently develop 
osteoporosis varied according to baseline BMD T-score (Table 2 and Figure 1). During 
follow-up, nine men (0.2% within T-score stratum) with higher baseline BMD developed 
osteoporosis. For those with moderate osteopenia and advanced osteopenia at baseline, the 
unadjusted times for 10% to develop osteoporosis were very similar to the adjusted time 
estimates of 8.5 (95% CI=6.7, 10.9) years and 2.7 (95% CI=2.1, 3.4) years, respectively.
Unadjusted estimates of the cumulative incidence of hip or clinical vertebral fracture as a 
function of testing interval length were similar to covariate-adjusted estimates (Table 3, 
Appendix Figure 2). The unadjusted estimated time (9.6 years, 95% CI=8.7 years, 10.6 
years) for 3% of men with higher baseline BMD to sustain a hip or clinical vertebral fracture 
was longer than the adjusted estimate of 7.1 (95% CI=6.0, 8.3) years. Otherwise, the 
unadjusted estimates of the time for 3% to develop a hip or clinical vertebral fracture were 
similar to the adjusted times of 4.8 (95% CI=3.8, 6.1) years for those with moderate 
osteopenia, and 4.1 (95% CI=3.1, 5.4) years for those with advanced osteopenia.
Unadjusted and covariate-adjusted estimates of the cumulative incidence of major 
osteoporotic fracture as a function of testing interval length were shorter than the analogous 
times for hip and clinical vertebral fracture (Appendix Table 1). The adjusted time for 3% to 
develop a major osteoporotic fracture ranged from 4.7 (95% CI=4.0, 5.7) years for men with 
higher BMD, to 2.6 (95% CI=1.9, 3.6) years for men with advanced osteopenia at baseline.
For all men aged ≥65 years with osteoporosis at baseline, the adjusted time for 3% to sustain 
a fracture was 1.7 (95% CI=1.0, 3.1) years for hip or clinical vertebral fracture and 1.0 (95% 
CI=0.5, 1.9) year for major osteoporotic fracture.
Full results of the sensitivity analyses are presented in the Appendix (Appendix Tables 2 and 
3 and associated text, Appendix Figure 3). The log-logistic model was found to most closely 
follow the non-parametric curve and was used in the main analysis.
Discussion
The time to incidence of osteoporosis was estimated according to baseline BMD T-score in 
older men without a history of hip or clinical vertebral fracture and without prior antifracture 
pharmacologic treatment. Less than 1% of men with higher BMD (baseline T-score > −1.50 
noted in 78% of the cohort) developed osteoporosis during 8.7 years of concurrent BMD and 
fracture follow-up. A significantly higher proportion of men with moderate or advanced 
osteopenia developed osteoporosis by the end of follow-up, but more often, hip or clinical 
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vertebral fracture occurred before osteoporosis developed. Twenty-nine percent of the hip 
and clinical vertebral fractures occurred in men with baseline normal BMD; at this T-score 
level, clinical practice guidelines do not recommend treatment in the absence of fragility 
fracture as there is no evidence that pharmacologic treatment prevents clinical fracture 
events among patients with normal BMD.
These findings for older men are consistent with findings for women aged 67 years and older 
with T-scores > −1.50 in an earlier study.15 Also similar to longitudinal studies of 
postmenopausal women,28–30 this study demonstrates that most older men who sustain a hip 
or clinical vertebral fracture do not have pre-existing osteoporosis. Fragility fractures in the 
absence of osteoporosis might be more common in men because men report a higher level of 
trauma associated with their fragility fractures compared with women.31,32 Men with poor 
physical condition are especially at risk; a 2008 longitudinal analysis demonstrated that 
older men with the worst performance on a repeated chair stand test had a substantially 
higher risk of hip fracture compared with men in the fastest quartile of this test (multivariate 
hazard ratio=8.15, 95% CI=1.46, 6.73).33 Also, men lose bone strength with age as a result 
of trabecular thinning and changes in cortical bone density, including both cortical thinning 
and increased porosity that are not easily identified by DXA BMD measurements.34 Like all 
prognostic tests, BMD testing cannot identify every individual who will have a future 
fragility fracture; therefore, other screening approaches (risk factor assessment, other 
imaging methods) and interventions to reduce risk factors for fracture (e.g., fall reduction) 
that are not related to BMD should continue to be investigated.
Despite supportive recommendations in some clinical practice guidelines,9–11,35,36 no 
standard of care exists for osteoporosis screening in older men at average risk of fracture. 
Medicare reimburses DXA scans in men for a limited number of disease indications, not 
including screening for primary prevention of fractures. Even after a major osteoporotic 
fracture, men are three times less likely than women to receive BMD testing and are unlikely 
to receive treatment.37,38 This study identified fracture rates in older men that were higher 
than rates for younger postmenopausal women,30 for whom policy statements encourage 
selective BMD screening.11,13,35 Clarification of the optimal target population of men for 
BMD screening/treatment could potentially have an important population-wide impact on 
fracture reduction if future RCTs demonstrate primary fracture prevention, especially if 
treating men with screen-detected osteoporosis at selected BMD thresholds will reduce their 
risk of hip and clinical vertebral fractures. As the evidence base for BMD screening and 
treatment continues to expand, the use of BMD testing among older men should be 
determined by informed decision making with patients and clinicians considering relevant 
data on BMD testing, clinical risk factors, and treatment.
Limitations
The study has several limitations and strengths. Results are limited to men who have already 
had one bone density test and therefore whose BMD is known. Precise time estimates were 
not possible beyond the actual follow-up time in MrOS. Of the 579 (9.7%) of the original 
MrOS participants who were excluded in this analysis, one third had a history of hip or 
clinical vertebral fracture or treatment at baseline. Subsequent DXA tests in these men 
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would be for post-fracture surveillance or treatment monitoring and would not meet the 
epidemiologic definition of screening. The cohort comprised men aged 65 years and older 
with a low overall prevalence of osteoporosis. The results are not generalizable to 
postmenopausal women or younger men, or individuals with secondary causes of 
osteoporosis. Ninety percent of the sample was white; results might differ for nonwhite 
individuals. The reported time intervals are not based on the time to incident radiographic 
vertebral fractures. A 2014 analysis of 4,332 MrOS participants with baseline and repeat 
radiographs found that 192 (4.4%) had an incident radiographic vertebral fracture.39 
Treatment of radiographic vertebral fracture has been shown to reduce incident hip and 
clinical vertebral fractures in postmenopausal women.40 However, because clinicians are 
unaware of these subclinical fractures, the time of onset of radiographic vertebral fractures is 
uncertain and cannot be used to calculate an optimal bone density screening interval. This 
suggests that the reported bone density testing intervals are conservative estimates for 
identification of patients who are likely to respond to treatment. Falls were not included in 
the evaluation of clinical risk factors for fracture, to be consistent with the International 
Osteoporosis Foundation’s caution in considering fall risk in estimating fracture probability 
because patients selected primarily on the basis of nonskeletal clinical risk factors (including 
several measures of fall risk) may respond less to antifracture agents compared to patients 
selected on the basis of low BMD.41,42 Falls are a critical factor in fracture risk, and 
interventions to reduce falls must be studied and implemented separately to maximize the 
effectiveness of fracture prevention programs. Strengths of the analysis include the large size 
of the cohort and the extended BMD and adjudicated fracture follow-up.
Conclusions
Community-dwelling men aged 65 years and older with baseline T-scores > −1.50 had a 
very low likelihood of developing osteoporosis over an average follow-up of 8.7 years. Ten 
percent of men with moderate and advanced osteopenia transitioned to osteoporosis in 
approximately 8 and 2 years, respectively. Most major osteoporotic fractures were not 
preceded by osteoporosis, suggesting that adjuncts to BMD testing should continue to be 
investigated to improve fracture prediction in older men.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Unadjusted cumulative incidence of osteoporosis according to baseline T-score range.
Note: The proportion of men who had transitioned to osteoporosis is plotted as a function of 
time. The cumulative incidence curves are estimated by parametric cumulative incidence 
models for interval-censored data. The dotted horizontal line shows where 10% of men have 
transitioned to osteoporosis; where this line intersects with each cumulative incidence curve, 
a vertical dotted line to the x-axis marks the estimated time interval. The time interval for 
men with baseline T-scores >−1.50 could not be calculated because of the very small 
number of fracture events (of the 4203 men with baseline T-scores >−1.50, nine [0.2%] 
developed osteoporosis during 8.7 years of BMD follow-up).
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Table 1
Characteristics of the Men in Osteoporotic Fractures in Men (MrOS) Study cohort
Baseline T-score >−1.50
Baseline T-score −1.50 
to −2.49 Baseline T-score ≤−2.50 All participants
Characteristicsa N=4,203 (77.6%) N=1,032 (19.1%) N=180 (3.3%) N=5,415
Age, mean years (SD) 73.2 (5.7) 74.8 (6.2) 75.8 (6.3) 73.6 (5.9)
 65–69 1,345 (32.0) 246 (23.8) 35 (19.4) 1,626 (30.0)
 70–74 1,245 (29.6) 263 (25.5) 42 (23.3) 1,550 (28.6)
 75–79 967 (23.0) 280 (27.1) 48 (26.7) 1,295 (23.9)
 ≥80 646 (15.4) 243 (23.5) 55 (30.6) 944 (17.4)
Weight, mean kg (SD) 85.1 (13.1) 77.8 (11.4) 73.0 (10.7) 83.3 (13.2)
BMI, kg/m2 27.9 (3.8) 26.0 (3.3) 24.9 (3.4) 27.4 (3.8)
 <25 965 (23.0) 410 (39.7) 100 (55.6) 1,475 (27.2)
 ≥25 3,238 (77.0) 622 (60.3) 80 (44.4) 3,940 (72.8)
Race
 White (Non-Hispanic) 3,747 (89.2) 947 (91.8) 159 (88.3) 4,853 (89.6)
 African American 195 (4.6) 16 (1.6) 5 (2.8) 216 (4.0)
 Asian 124 (3.0) 42 (4.1) 8 (4.4) 174 (3.2)
 Hispanic 89 (2.1) 16 (1.6) 4 (2.2) 109 (2.0)
 Other 48 (1.1) 11 (1.1) 4 (2.2) 63 (1.2)
Years of education
 Less than high school 266 (6.3) 65 (6.30) 13 (7.2) 344 (6.35)
 High school/Some college 1,681 (40.0) 409 (39.6) 72 (40.0) 2,162 (39.9)
 College/Some grad school 1,229 (29.2) 288 (27.9) 63 (35.0) 1,580 (29.2)
 Grad school 1,027 (24.4) 270 (26.2) 32 (17.8) 1,329 (24.5)
Previous fracture after age 50
 Yes 766 (18.2) 258 (25.0) 59 (32.8) 1,083 (20.0)
 No 3,437 (81.8) 774 (75.0) 121 (67.2) 4,332 (80.0)
Current smoker
 Current 140/4,202 (3.3) 39 (3.8) 11 (6.1) 190/5,414 (3.5)
 Past 2,488/4,202 (59.2) 582 (56.4) 98 (54.4) 2,056/5414 (38.0)
 Never 1,574/4,202 (37.5) 411 (39.8) 71 (39.4) 3,168/5,414 (58.5)
Alcohol consumption
 <21 drinks per week 4,023 (95.7) 1,001 (97.0) 173 (96.1) 5,197 (96.0)
 ≥21 drinks per week 180 (4.28) 31 (3.00) 7 (3.89) 218 (4.03)
History of parental hip fracture
 Yes 497/2,968 (16.7) 164/742 (22.1) 28/146 (19.2) 689/3,856 (17.9)
 No 1,511/2,968 (50.9) 327/742 (44.1) 75/146 (51.4) 1,913/3,856 (49.6)
 Don’t know 960/2,968 (32.3) 251/742 (33.8) 43/146 (29.5) 1,254/3,856 (32.5)
Rheumatoid arthritis
 Yes 221 (5.3) 44 (4.3) 6 (3.3) 271 (5.0)
 No 3,982 (94.7) 988 (95.7) 174 (96.7) 5,144 (95.0)
Am J Prev Med. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gourlay et al. Page 14
Baseline T-score >−1.50
Baseline T-score −1.50 
to −2.49 Baseline T-score ≤−2.50 All participants
Characteristicsa N=4,203 (77.6%) N=1,032 (19.1%) N=180 (3.3%) N=5,415
Oral glucocorticoid ever-use
 Yes 80/3,323 (2.4) 20/804 (2.5) 9/128 (7.0) 109/4,255 (2.6)
 No 3,243/3,323 (97.6) 784/804 (97.5) 119/128 (93.0) 4,146/4,255 (97.4)
Bone mineral density T-score, mean (SD)b
 Femoral neck −0.23 (0.89) −1.72 (0.44) −2.38 (0.63) −0.59 (1.06)
  range −4.25, 6.17
 Total hip 0.53 (0.96) −0.98 (0.60) −1.81 (0.75) 0.16 (1.14)
  range −4.00, 6.73
 Lumbar spine 1.67 (2.15) −0.35 (1.61) −1.57 (1.70) 1.17 (2.25)
  range −3.93, 15.20
Prevalence of osteoporosisc
 Definition 1 0 0 180 (100.0) 180 (3.3)
 Definition 2 0 184 (17.8) 180 (100.0) 364 (6.7)
 Definition 3 0 0 114 (63.3) 114 (2.1)
 Definition 4 0 0 119 (66.1) 119 (2.2)
Hip or clinical vertebral fracture by 
study endd
169 (4.0) 110 (10.7) 38 (21.1) 317 (5.9)
 Hip fracture 94 (2.2) 75 (7.3) 25 (13.9) 194 (3.6)
 Clinical vertebral fracture 75 (1.8) 35 (3.4) 13 (7.2) 123 (2.3)
Antifracture treatment by study end 143 (3.4) 131 (12.7) 62 (34.4) 336 (6.2)
 Bisphosphonate 141 (3.4) 130 (12.6) 59 (32.7) 330 (6.1)
 Calcitonin 2 (<0.1) 1 (<0.1) 2 (1.1) 5 (<0.1)
 Teriparatide 0 (0.0) 0 (0.0) 1 (0.5) 1 (<0.1)
Total fracture follow-up time, years
 Mean (SD) 11.1 (3.6) 10.7 (3.8) 10.2 (4.1) 11.0 (3.7)
 Median 13.0 12.7 12.2 12.9
 Minimum 0.04 0.08 0.7 0.04
 Maximum 14.8 14.8 14.6 14.8
Concurrent BMD and fracture follow-up time, yearse
 Mean (SD) 5.2 (2.3) 4.9 (2.4) 4.7 (2.6) 5.1 (2.3)
 Median 6.5 5.8 5.3 6.5
 Minimum 0 0 0 0
 Maximum 8.7 8.6 8.1 8.7
BMD, bone mineral density
aValues are N (% of T-score group) unless otherwise specified. N/non-missing values are presented if data were incomplete except for rheumatoid 
arthritis (missing value treated as no disease).
b
Maximum T-score values confirmed as valid by the MrOS Data Coordinating Center
c
Tabulations of disease events according to the following four definitions of osteoporosis are presented in Appendix Tables 4–7.
Definition 1. Lowest T-score at the femoral neck or total hip or lumbar spine calculated using BMD norms for young white women
Am J Prev Med. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gourlay et al. Page 15
Definition 2. Lowest T-score at the femoral neck or total hip or lumbar spine calculated using BMD norms for young white men
Definition 3. Lowest T-score at the femoral neck calculated using BMD norms for young white women
Definition 4. Lowest T-score at the femoral neck or total hip calculated using BMD norms for young white women
d
Tabulations of first hip or clinical vertebral fracture before a competing risk occurred
e
Includes participants who had one baseline DXA test, then developed a competing risk before osteoporosis, treatment or major fracture (0 
concurrent BMD and fracture follow-up)
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Table 2
Time for 10% of Men Without Osteoporosisa or Treatment at Baseline to Develop Osteoporosis, According to 
Baseline T-score Range
Baseline T-score range Osteoporosis events, N (%) Time interval for 10% of participants to develop osteoporosisb
Unadjusted years (95% CI) Adjusted years (95% CI)
>−1.50 9/4203(0.21) ---- ----
−1.50 to −1.99 35/680 (5.15) 8.57 (6.67, 10.99) 8.51 (6.67, 10.86)
−2.00 to −2.49 73/352 (20.74) 2.59 (2.03, 3.30) 2.68 (2.12, 3.40)
aOsteoporosis defined as lowest T-score ≤-2.5 at femoral neck or total hip or lumbar spine, calculated using bone mineral density (BMD) norms for 
young white women
b
Estimated time to osteoporosis (competing risks: incident hip or clinical vertebral fracture, antifracture treatment or death), computed by quantile 
estimates based on the fitted log logistic models, stratified by baseline lowest femoral neck, total hip or lumbar spine T-score (lowest T-score −1.50 
to −1.99 vs. −2.00 vs. −2.49), and adjusted for mean-centered age, mean-centered BMI and race.
Note: Time estimates for the T-score>−1.50 group could not be calculated due the very small number of endpoint events, leading to excessive 
extrapolation beyond the observed BMD follow-up of 8.7 years.
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Table 3
Time for 3% of Men Without Osteoporosisa or Treatment at Baseline to Sustain a Hip or Clinical Vertebral 
Fracture, According to Baseline T-score Range
Baseline T-score range Fracture events, N (%) Time interval for 3% of participants to sustain a hip or clinical vertebral fractureb
Unadjusted years (95% CI) Adjusted years (95% CI)
>−1.50 169/4203 (4.02) 9.59 (8.69, 10.59) 7.09 (6.02, 8.34)
−1.50 to −1.99 68/680 (10.00) 4.37 (3.41, 5.61) 4.83 (3.84, 6.09)
−2.00 to −2.49
42/352 (11.93)
3.51 (2.58, 4.79)
4.06 (3.05, 5.40)
a
Lowest T-score ≤−2.5 at femoral neck or total hip or lumbar spine, calculated using bone mineral desnity norms for young white women
b
Estimated time to hip or clinical vertebral fracture (competing risks: incident osteoporosis, antifracture treatment or death), computed by quantile 
estimates based on the fitted log logistic models, stratified by baseline lowest femoral neck or total hip or lumbar spine T-score (lowest T-score 
−1.50 to −1.99 vs. −2.00 vs. −2.49), and adjusted for mean-centered age, mean-centered BMI and race.
Note: Estimates greater than 8.7 years (italicized) have questionable reliability due to excessive extrapolation required for 3% to transition to hip or 
clinical vertebral fracture.
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